Search PubMed⌕ Search

Biomedical subjects

O O Ajayi

Publications and source records attributed to O O Ajayi.

31 records · Page 2Linked to original sources
PubMed1971

Gastro-intestinal manifestations of Burkitt tumour.

Sixty-six cases of Burkitt's lymphoma were studied. Twenty-five of the cases had tumour involvement of the bowel. The commonest site of gastro-intestinal involvement was the stomach. No lesions were found in the oesophagus and rectum except in one case where the tumour was thought to have extended to the lower oesphagus from the cardia of the stomach. Attention is drawn to complications that may arise which require emergency measures and also to the infrequency of symptoms directly referable to bowel lesions. Illustrative case reports are given.

Adolescent↗
PubMedDate not supplied

Frequency of human toxocariasis in Jos, Plateau State, Nigeria.

The enzyme-linked immunosorbent assay (Elisa) was used to examine sera of 104 children and adults in Jos, Plateau State, Nigeria for anti-toxocaral antibodies, out of which 31 (29.8%) were reactive. The seropositive rates were 30.4% for adults, 29.6% for children, 34% for females and 25.9% for males. However, the differences were not significant by age and sex. A highly significant association (p < 0.001) was observed between seropositivity and geography but none between seropositivity and dog ownership (p > 0.05).

Adolescent↗
PubMedDate not supplied

Breast cancer in Nigeria.

Breast cancer is now the commonest malignancy affecting women in Nigeria. It is likely to become an important public health issue in the next millennium. Recent years have witnessed an explosion in knowledge about the basic sciences of the disease, including the genetic basis and the pathology. These changes are leading to revisions in the management of the disease with a positive impact on prognosis. In this review, the recent developments in the various aspects of breast cancer are reviewed with reference to how they affect the disease in this environment.

Breast Neoplasms↗
PubMedDate not supplied

Tamoxifen in the management of advanced breast carcinoma in Nigerian women.

Twenty-nine Nigerian women with advanced breast carcinoma treated with Tamoxifen (Nolvadex ICI) at a dosage of 20 mg twice daily have been reviewed. Eight of 26 evaluable patients had objective response (31%). No statistically significant association was found between response rate and menopausal status, previous chemotherapy or disease free interval. The drug was well tolerated with a low incidence of side effects. This study suggests that Tamoxifen is a useful drug in the adjuvant management of patients with advanced breast carcinoma in Nigeria.

Adult↗